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Introduction
Fatigue, defined as the subjective feeling of tired-
ness or exhaustion, is a common complaint in 
today’s society.1–5 It is a major distressing and per-
sisting symptom in many chronic diseases, includ-
ing Chronic Obstructive Pulmonary Disease 
(COPD).6 Fatigue is considered the second most 
important symptom of COPD after dyspnoea,7,8 
and significantly impairs patients’ functional per-
formance and quality of life (QoL).9–12 In patients 
with COPD, prevalence estimates of mild-to-severe 
fatigue range between 47% and 72%.7,8,13–17 
Corresponding data from elderly, non-COPD 
subjects are limited. Most fatigue-related studies 
lack a non-COPD control group;7,8,15–17 and those 
studies that included a non-COPD control group 
report inconsistent results. Most of these studies 
indicate that the prevalence of fatigue is signifi-
cantly higher in patients with COPD compared 
with elderly non-COPD subjects.13,14,18,19 
Nevertheless, these studies were limited in size 
(between 30 and 37 control participants). One 
large population-based study, including 470 sub-
jects with COPD and 659 without COPD, did not 
find a difference in fatigue level between patients 
with COPD and subjects without COPD.20
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Abstract
Background: The objective of this study was to compare fatigue levels between subjects with 
and without COPD, and to investigate the relationship between fatigue, demographics, clinical 
features and disease severity.
Methods: A total of 1290 patients with COPD [age 65 ± 9 years, 61% male, forced expiratory 
volume in 1 s (FEV1) 56 ± 19% predicted] and 199 subjects without COPD (age 63 ± 9 years, 51% 
male, FEV1 112 ± 21% predicted) were assessed for fatigue (Checklist Individual Strength-
Fatigue), demographics, clinical features and disease severity.
Results: Patients with COPD had a higher mean fatigue score, and a higher proportion of 
severe fatigue (CIS-Fatigue score 35 ± 12 versus 21 ± 11 points, p < 0.001; 49 versus 10%, 
p < 0.001). Fatigue was significantly, but poorly, associated with the degree of airflow limitation 
[FEV1 (% predicted) Spearman correlation coefficient = −0.08, p = 0.006]. Multiple regression 
indicated that 30% of the variance in fatigue was explained by the predictor variables.
Conclusions: Severe fatigue is prevalent in half of the patients with COPD, and correlates 
poorly with the degree of airflow limitation. Future studies are needed to better understand 
the physical, psychological, behavioural, and systemic factors that precipitate or perpetuate 
fatigue in COPD.
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Despite the fact that fatigue is an important daily 
symptom in COPD, it is often ignored in clinical 
practice and research.11,21 Its aetiology is under-
studied and therefore subject to dispute, compli-
cating the development of effective interventions 
to manage mild-to-severe fatigue in patients with 
COPD.22 Moreover, it remains unclear whether, 
and to what extent, fatigue is related to the lung 
function impairment itself. The association 
between fatigue and the degree of COPD severity 
has been studied before, but conclusions were con-
tradictory.9,16,18,19,23,24 Based on the input of 
experts in the field of respiratory research and care, 
as well as patients with chronic lung disease, fatigue 
is prioritised as a research topic.25
A better understanding of the nature of fatigue 
and its underlying causes in patients with COPD 
will provide guidance for the development of 
pharmacological and nonpharmacological inter-
ventions for this important yet ignored symp-
tom. Therefore, the objectives of this study were 
twofold: to compare fatigue levels between sub-
jects with and without COPD; and to study the 
relationship between the severity of fatigue, 
demographic characteristics, clinical features 
and disease severity.
Methods
Study design and participants
The present study is a cross-sectional, compara-
tive analysis combining baseline data from two 
prospective, observational studies and one rand-
omized controlled trial [NL42721.060.12/M12-
1280; P02.1411L CMO-nr 2002/047; and 
NCT00940355 (see clinicaltrials.gov)]. Details 
of these studies are published elsewhere.26,27 In 
addition, data from patients who were referred 
to a pulmonologist for a comprehensive health 
status assessment at the Amphia Hospital in 
Breda or the Radboud University Medical 
Centre in Nijmegen (both in the Netherlands) 
between April 2013 and June 2017, were con-
veniently used for the analyses.28–30 Patients 
were included in the current study if they had a 
diagnosis of COPD [Global initiative for chronic 
Obstructive Lung Disease (GOLD)],31 with a 
postbronchodilator forced expiratory volume in 
1 s (FEV1) to forced vital capacity (FVC) ratio, 
FEV1/FVC <0.7. This resulted in a total sample 
of 1290 outpatients with COPD from a second-
ary care setting.
The control group were all non-COPD partici-
pants from the two observational studies. In 
study NL42721.060.12/M12-1280, the resident 
proxy of the patient was recruited (defined as a 
person living together with a patient with COPD, 
regardless of whether they provide informal care 
to the patient with COPD). The recruitment 
area of this observational study concerned the 
southern-eastern part of the Netherlands. In 
study P02.1411L (CMO-nr 2002/047), healthy 
controls (individuals with no pre-existing medi-
cal conditions) were recruited by an advertise-
ment in a regional newspaper (Nijmegen and 
surroundings, the Netherlands). The control 
groups of these studies were comparable in terms 
of marital status and working status but differed 
in educational level (16% versus 46%, respec-
tively, completed secondary general education, 
p < 0.001). Non-COPD control subjects had no 
previous history of COPD and had a FEV1/FVC 
ratio greater than 0.7. In total, 199 non-COPD 
control subjects fulfilled the inclusion criteria 
and were selected for the current analysis.
The participating centres’ ethical review boards 
approved the two observational studies and one 
randomized controlled trial (NL42721.060.12/
M12-1280; P02.1411L CMO-nr 2002/047; and 
NCT00940355). All participants in these studies 
provided written informed consent. With regard 
to the present analysis, consistent with the Dutch 
Central Committee on Research Involving 
Human Subjects guidance, reconsent for the pro-
cessing of personal data was not required for sub-
jects who have participated in approved studies 
within the scope of the Medical Research 
Involving Human Subjects Act (WMO). 
Furthermore, the Secretary of the Medical Ethics 
Committee of University Hospital Maastricht 
and Maastricht University (the medical ethical 
committee in our region) confirmed that addi-
tional ethics committee approval and informed 
consent were not needed for the present retro-
spective observational analysis. Data collected 
from patients in the Amphia Hospital in Breda or 
the Radboud University Medical Centre in 
Nijmegen were collected in the clinical routine 
and anonymized for research purposes according 
to local procedures. Due to the retrospective 
nature of the current analysis, and because the 
participants were subjected to usual care, the 
Medical Ethical Committee of the Radboudumc 
considered that it did not fall within the remit of 
the WMO, and, therefore, did not require 
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informed consent nor additional ethics approval. 
Data of the participants from the Amphia Hospital 
in Breda or the Radboud University Medical 
Centre in Nijmegen were used in the study by 
Koolen and colleagues,30 and in the current 
analysis.
Measures
Fatigue was measured by the subjective fatigue 
subscale of the Checklist Individual Strength (CIS-
Fatigue).32 The CIS-Fatigue consists of eight items 
scored on a seven-point Likert scale. The scores 
range from 8 (normal fatigue) to 56 (most severe 
fatigue). A score of 26 or lower indicates normal 
fatigue, scores between 27 and 35 indicate moder-
ate fatigue and a score of 36 or higher indicates 
severe fatigue. The CIS-Fatigue is a standardized 
and validated questionnaire that has been used in 
healthy subjects,33–35 and among various patient 
populations, including COPD.16,27,32,36–38
Demographic data were collected from both sub-
jects with COPD as well as controls without 
COPD, to provide information on their age, gen-
der, working situation (yes/no paid job), marital 
status (yes/no partner), and education level (inter-
mediate vocational education or lower/secondary 
general education or higher).
Clinical features included smoking status (yes/no 
current smoker), pack years [(number of cigarettes 
smoked per day/20) × number of years smoked], 
the number of medications in use, and the comor-
bidity burden [Charlson Comorbidity Index 
(CCI)].39 Body composition was assessed and 
expressed as body mass index (BMI). BMI was 
defined as the body mass in kilograms (kg) divided 
by the squared height in meters (kg/m2) and 
 categorized in four subgroups: underweight 
(BMI < 21 kg/m2), normal weight (BMI 21–25 kg/m2), 
overweight (BMI 25–30 kg/m2), or obese 
(BMI > 30 kg/m2).40 The use of long-term oxygen 
therapy (yes/no) was assessed in patients only.
Disease severity was assessed by spirometry, the 
number of exacerbations in the previous year 
(patients only; defined as an acute event charac-
terised by a worsening of the patient’s respiratory 
symptoms, that is, beyond the normal day-to-day 
variations and leads to a change in medication),41 
the degree of dyspnoea [using the modified 
Medical Research Council (mMRC) scale] 
(patients only),42 and the disease-specific health 
status [COPD Assessment Test (CAT)] (patients 
only). Airflow obstruction was evaluated with 
postbronchodilator spirometry according to the 
ATS/ERS guidelines.43 Based on the degree of 
airflow limitation patients were classified accord-
ing to the 2007 GOLD stages: GOLD grade 1 
(FEV1 ⩾80% of predicted), GOLD grade 2 
(50%⩽ FEV1 <80% of predicted), GOLD grade 
3 (30%⩽ FEV1 <50% of predicted), GOLD 
grade 4 (FEV1 <30% of predicted).44
Statistical analyses
Data were analysed using SPSS (V.25.0 for 
Windows, Chicago, IL, USA). Categorical data 
were presented as frequencies and percentages. 
Continuous variables were tested for normality 
using the Shapiro–Wilk test, and presented as 
mean ± standard deviation (SD) or median and 
interquartile range (IQR), as appropriate. 
Differences between patients and non-COPD con-
trol subjects were analysed with the Chi-square test 
(categorical data), Student’s t test for independent 
groups (continuous data), or the Mann–Whitney U 
test (skewed continuous data). The Kruskall–Wallis 
test was administered to determine if there were 
differences between patients with normal, mild, or 
severe fatigue. A priori, the level of significance was 
set at p < 0.01 (two-tailed).
Correlations were assessed by the nonparametric 
Spearman’s rank correlation. The magnitude of 
the relationships was interpreted using the effect 
size provided by Cohen. Correlation coefficients 
in the order of 0.10 represent a small association, 
coefficients of 0.30 are a medium association, and 
coefficients of 0.50 represent a large effect size.45 
Last, multiple regression analysis was performed 
to determine how much of the variation in the 
fatigue level could be explained by the predictor 
variables. The predictor variables were those that 
significantly correlated with fatigue (p < 0.10). 
Independent variables were checked for multicol-
linearity by inspecting the tolerance values/vari-
ance inflation factors (VIF) and the correlation 
coefficients of the independent variables. There is 
no evidence for multicollinearity when tolerance 
values are greater than 0.1 (which is a VIF less 
than 10) and correlation coefficients below 0.7. 
The CAT questionnaire was left out, since it was 
expected that the CAT would explain a large 
share of the variance of fatigue, considering that 
the CAT questionnaire includes a question on the 
participant’s energy level.
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Results
Background characteristics
Table 1 presents the background characteristics of 
the 1290 COPD patients and the 199 non-COPD 
participants. The vast majority of patients with 
COPD had moderate-to-severe COPD (49% 
GOLD stage II, and 33% GOLD stage III). The 
groups were comparable in terms of age, propor-
tion of current smokers, education, and working 
situation. The proportion of men in the COPD 
sample tended to be higher compared with the 
non-COPD control group (p = 0.011). Compared 
with the non-COPD control group, patients with 
COPD lived more often alone, had a worse lung 
function, had a lower BMI, had a higher number 
of comorbidities, and used more medications.
Fatigue
Among patients with COPD, 25.5% experienced 
normal fatigue, 26.0% mild fatigue, and 48.5% 
severe fatigue. In comparison, 73.4% of the non-
COPD subjects reported normal fatigue, 16.6% 
mild fatigue, and 10.1% severe fatigue (p < 0.001; 
Figure 1). Moreover, mean fatigue scores were 
significantly higher in the COPD group versus the 
non-COPD group (Table 1). Compared with 
male patients with COPD, female patients had a 
higher mean fatigue score, and, in turn, a higher 
proportion of severe fatigue (CIS-Fatigue score 
34 ± 12 versus 37 ± 12 points, p < 0.001; 45 versus 
54% with severe fatigue, respectively; p < 0.001; 
see Table S1). The mean fatigue score of the 
women and men in the non-COPD control group 
were comparable (22 ± 12 versus 21 ± 11 points, 
respectively; p = 0.39; see Table S2). Within the 
non-COPD controls, the controls from the 
NL42721.060.12/M12-1280 study had a higher 
mean fatigue score compared with the control 
group selected from the P02.1411L CMO-nr 
2002/047 study (CIS-Fatigue score 24 ± 12 ver-
sus 16 ± 8 points; p < 0.001; see Table S3).
Differences among patients with normal, mild 
or severe fatigue
Table 2 lists the characteristics of patients with 
COPD stratified by the degree of fatigue. Most 
notably, patients with severe fatigue had greater 
dyspnoea (mMRC grade ⩾2), compared with 
patients with normal and mild fatigue (normal 
fatigue: 28%; mild fatigue: 49%; severe fatigue: 
65%; p < 0.001; Figure 2a). Moreover, the patients 
who experienced severe fatigue were somewhat 
younger, had a worse lung function, were more 
often smokers, used a higher number of medica-
tions, and experienced more exacerbations in the 
last 12 months. Disease-specific health status, 
measured with the CAT, was more impaired in 
patients with severe fatigue compared with subjects 
with normal and mild fatigue. The groups were 
comparable in terms of pack years, marital status, 
the number of patients that used oxygen therapy, 
self-reported comorbidities, education level, work-
ing status, and BMI. Patients categorized as being 
underweight as well as obese experienced more 
severe fatigue than patients classified as having a 
normal or overweight BMI (Figure 2b).
Factors associated with fatigue in patients with 
COPD
Education level, work situation, and BMI showed 
no significant relation with fatigue (p > 0.10). The 
factors gender (rs = 0.113, p < 0.001), age 
(rs = −0.087, p = 0.002), GOLD grade (rs = 0.076, 
p = 0.006), marital status (rs = −0.096, p = 0.001), 
smoking status (rs = 0.127, p < 0.001), pack years 
(rs = 0.129, p = 0.073), the use of long-term oxygen 
therapy (rs = 0.146, p = 0.043), comorbidity burden 
(rs = 0.104, p = 0.016), number of COPD-related 
exacerbations in the previous year (rs = 0.199, 
p < 0.001), and lung function (FEV1 (L) rs = −0.085, 
p = 0.002; FEV1 (% predicted) rs = −0.076, 
p = 0.006; FVC (L) rs = −0.143, p < 0.001) (Figure 
3) showed significant but low associations with 
fatigue (p < 0.10). The number of medications 
(rs = 0.353, p < 0.001) and the degree of dyspnoea 
(rs = 0.347, p < 0.001) showed the strongest rela-
tion with fatigue. Moreover, as expected, fatigue was 
strongly correlated with the CAT questionnaire 
(rs = 0.584, p < 0.001) (Figure 4).
R2 for the overall model was 29.7%. Gender, age, 
marital status, smoking status, pack years, FEV1 (% 
predicted), FVC (L), the use of long-term oxygen 
therapy, number of medications, the comorbidity 
burden (CCI), the degree of dyspnoea (mMRC), 
and the number of exacerbations in the previous 
year significantly predicted fatigue in COPD, F(12, 
176) = 7.630 (p < 0.001; in which 12 indicates the 
regression degrees of freedom, 176 the residual 
degrees of freedom, 7.630 the obtained F value). 
The variable ‘GOLD stadia’ was excluded from the 
multiple regression, since it was highly intercorre-
lated with the variable ‘FEV 1 (% predicted)’ (bivar-
iate correlation coefficient of −0.91, respectively), 
YMJ Goërtz, MA Spruit et al.
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Table 1. Background characteristics of COPD patients (n = 1290) and non-COPD participants (n = 199).
General characteristics n COPD (n = 1290) n Non-COPD (n = 199) p-value
Male, n (%) 1290 784 (60.8) 199 102 (51.3) 0.011
Age, years 1290 64.7 ± 9.4 199 63.1 ± 9.4 0.053
Current smoker, n (%) 1232a 380 (30.8) 199 45 (22.6) 0.018
Pack years 194b 40.3 ± 20 133l 16.8 ± 20.6 <0.001
Long term oxygen therapy, n (%) 194c 54 (27.8) - - -
Charlson comorbidity index, points 543d 2 (1–3) 66m 1 (0–2) <0.001
COPD assessment test, points 696e 19 (13–25) - - -
Partner, n (%) 1250f 951 (76.1) 199 169 (84.9) 0.006
Level of education, n (%) 1226g 199 0.585
  Intermediate vocational education or 
lower
889 (72.5) 148 (74.4)  
 Secondary general education or higher 337 (27.5) 51 (25.6)  
Working status, n (%) 1237h 198n 0.415
 Paid work 310 (25.1) 55 (27.8)  
 No paid work 927 (74.9) 143 (72.2)  
Body composition  
 BMI (kg/m2) 1290 26 ± 5 199 27.5 ± 4.5 <0.001
  Underweight, n (%) 203 (15.7) 9 (4.5) <0.001
  Normal weight, n (%) 384 (29.8) 58 (29.1)  
  Overweight, n (%) 455 (35.3) 82 (41.2)  
  Obese, n (%) 248 (19.2) 50 (25.1)  
Spirometry  
 FEV 1 (% predicted) 1290 55.5 ± 18.9 199 111.5 ± 20.8 <0.001
 FEV 1
(Litres)
1290 1.6 ± 0.6 199 3.1 ± 0.8 <0.001
 FVC (Litres) 1290 3.5 ± 1 199 4 ± 1.1 <0.001
GOLD, n (%) 1290 -
 I 131 (10.2) - -  
 II 631 (48.9) - -  
 III 430 (33.3) - -  
 IV 98 (7.6) - -  
Medications in use, nr 194i 7 (5–11) 133o 2 (1–5) <0.001
(Continued)
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and therefore reflects the same concept, that is, air-
flow limitation. Of all independent variables, dysp-
noea as measured by the mMRC scale was 
responsible for the largest unique contribution 
(Beta = 0.32, p < 0.001) (Table S4).
Discussion
The most significant result of this study is that 
severe fatigue is more prevalent in patients with 
COPD compared with subjects without COPD. 
Furthermore, fatigue appears to be significantly, 
but poorly associated with the degree of airflow 
limitation. Moreover, 70% of the variance in 
fatigue scores cannot be explained by demograph-
ics, clinical features and disease severity.
Prevalence of fatigue
A quarter of patients with COPD experienced mild 
fatigue, whereas half had severe fatigue. In compari-
son, 17% of subjects without COPD experienced 
mild fatigue and only 10% had severe fatigue. These 
results indicate that severe fatigue is substantially 
more prevalent in patients with COPD compared 
with elderly without COPD (p < 0.001). Despite its 
high prevalence and significant negative health con-
sequences,9–12 fatigue remains often undiagnosed, 
and, in turn, untreated.11,21 Therefore, the preva-
lence emphasizes the clinical relevance of assessing 
fatigue in patients with COPD. Nevertheless, a bet-
ter understanding of the factors that precipitate or 
perpetuate fatigue in patients with COPD is needed, 
to develop fatigue reducing or coping interventions 
for this important, yet disregarded, symptom in 
patients with COPD.22,46
Figure 1. Prevalence of normal, mild and severe 
fatigue in persons with and without COPD.
COPD, chronic obstructive pulmonary disease.
General characteristics n COPD (n = 1290) n Non-COPD (n = 199) p-value
Dyspnoea  
 mMRC, points 744j 2(1–3) -
 <2 mild dyspnoea, n (%) 346 (46.5) - - -
 ⩾2 severe dyspnoea, n (%) 398 (53.5) - -  
Fatigue  
 CIS-Fatigue, points 1290 35 (26–44) 199 20 (12–28) <0.001
 Normal fatigue, n (%) 329 (25.5) 146 (73.4) <0.001
 Mild fatigue, n (%) 335 (26.0) 33 (16.6)  
 Severe fatigue, n (%) 626 (48.5) 20 (10.1)  
Exacerbations last 12 months, n 713k 1 (0–2) - - -
Data are shown as mean ± SD, median (IQR) or n(%).
BMI, body mass index; CIS-Fatigue, checklist individual strength subscale fatigue; COPD, chronic obstructive pulmonary disease; FEV1 (% 
predicted), forced expiratory volume over 1 s of predicted; FVC, forced volume capacity; GOLD, global initiative for chronic obstructive lung disease; 
IQR, interquartile range; mMRC, modified Medical Research Council dyspnoea scale; SD, standard deviation.
a58 missing values; b1096 missing values; c1096 missing values; d747 missing values; e594 missing values; f40 missing values; g64 missing values; 
h53 missing values; i1096 missing values; j546 missing values; k572 missing values; l66 missing values; m133 missing values; n1 missing values; o66 
missing values.
Table 1. (Continued)
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Table 2. Characteristics of COPD patients with normal, mild or severe fatigue.
Fatigue level – COPD patients n Normal 
fatigue 
(n = 329)
n Mild 
fatigue 
(n = 335)
n Severe 
fatigue 
(n = 626)
p-value
Male, n (%) 329 225(68.4) 335 208(62.1) 626 351(56.1) 0.001
Age, years 329 65.4 ± 8.7 335 65.6 ± 9.4 626 63.9 ± 9.8 0.006
Current smoker, n (%) 318a 88(27.7) 312l 71(22.8) 602x 221(36.7) <0.001
Pack years 35b 37 ± 18.3 57m 38.3 ± 19.4 102y 42.5 ± 20.7 0.300
Long term oxygen therapy, n (%) 35b 6(17.1) 57n 15(26.3) 102z 33(32.4) 0.213
Charlson comorbidity index, 
points
113d 2(1–3) 129o 2(1–3) 301aa 2(1–4) 0.114
COPD Assessment Test, points 144e 11(8–14) 171p 17(12–21) 381ab 22(18–27) <0.001
Partner, n (%) 323f 258(79.9) 329q 257(78.1) 598ac 436(72.9) 0.037
Level of education, n (%) 325g 320r 581ad 0.076
  Intermediate vocational 
education or lower
220(67.7) 237(74.1) 432(74.4)  
  Secondary general education 
or higher
105(32.3) 83(25.9) 149(25.6)  
Working status, n (%) 322h 323s 592ae 0.548
 Paid work 88(27.3) 79(24.5) 143(24.2)  
 No Paid work 234(72.7) 244(75.5) 449(75.8)  
Body composition  
 BMI (kg/m2) 329 25.6 ± 4.3 335 25.9 ± 4.6 626 26.3 ± 5.6 0.390
  Underweight, n (%) 53(16.1) 335 40(11.9) 626 110(17.6) 0.002
  Normal weight, n (%) 104(31.6) 110(32.8) 170(27.2)  
  Overweight, n (%) 123(37.4) 131(39.1) 201(32.1)  
  Obese, n (%) 49(14.9) 54(16.1) 145(23.2)  
Spirometry  
 FEV 1 (% predicted) 329 59.1 ± 19 335 54.8 ± 19.4 626 54.1 ± 18.3 0.001
 FEV 1 (Litres) 329 1.7 ± 0.6 1.5 ± 0.7 1.5 ± 0.6 <0.001
 FVC (Litres) 329 3.7 ± 1 3.4 ± 1 3.4 ± 1 <0.001
GOLD, n (%) 329 335 626 0.005
 I 44(13.4) 38(11.3) 49(7.8)  
 II 173(52.6) 152(45.4) 306(48.9)  
 III 98(29.8) 111(33.1) 221(35.3)  
(Continued)
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The current findings on the prevalence of fatigue 
in patients with COPD and non-COPD partici-
pants are in line with previous studies,13,14,18,19 
although, the control groups of those studies were 
not only limited in size, they were not always well 
characterized. For example, Theander and col-
leagues reported fatigue every day during the pre-
ceding month in nearly half of the patients, as 
measured with the Fatigue Impact Scale (FIS), 
compared with 13.5% of the control group 
Figure 2. (a) Fatigue scores (mean and 95% CI) after stratification for the degree of dyspnoea: grade 0–4 on 
the mMRC dyspnoea scale. (b) Fatigue scores (mean and 95% CI) after stratification for the BMI classification 
(underweight BMI < 20 kg/m2, normal weight BMI 20–25 kg/m2, overweight BMI 25–30 kg/m2, obese BMI > 
30 kg/m2).
BMI, body mass index; CI, confidence interval; mMRC, modified Medical Research Council.
Fatigue level – COPD patients n Normal 
fatigue 
(n = 329)
n Mild 
fatigue 
(n = 335)
n Severe 
fatigue 
(n = 626)
p-value
 IV 14(4.3) 34(10.1) 50(8.0)  
Medications in use, n 35i 6(3–9) 57t 7(4–9.5) 102af 8(6–13) 0.001
Dyspnoea  
 mMRC, points 149j 1(0–2) 192u 1(0–3) 403ag 2(1–3) <0.001
 <2 mild dyspnoea, n (%) 107(71.8) 192v 98(51.0) 403ah 141(35.0) <0.001
 ⩾2 severe dyspnoea, n (%) 42(28.2) 94(49.0) 262(65.0)  
Exacerbations last 12 months, n 149k 0(0–1) 183w 1(0–2) 381ai 1(0–2) <0.001
Data are shown as mean ± SD, median (IQR) or n(%). p-value: Kruskall–Wallis comparing patients with normal, mild and severe fatigue.
BMI, body mass index; CIS-Fatigue, checklist individual strength subscale fatigue; COPD, chronic obstructive pulmonary disease; FEV1 (% 
predicted), forced expiratory volume over 1 s of predicted; FVC, forced volume capacity; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; IQR, interquartile range; mMRC, modified Medical Research Council dyspnoea scale; SD, standard deviation.
a11 missing values; b294 missing values; c294 missing values; d216 missing values; e185 missing values; f6 missing values; g4 missing values; h7 
missing values; i294 missing values; j180 missing values; k180 missing values; l23 missing values; m278 missing values; n278 missing values; o206 
missing values; p164 missing values; q6 missing values; r21 missing values; s12missing values; t278 missing values; u421 missing values; v143 
missing values; w152 missing values; x24 missing values; y524 missing values; z524 missing values; aa325 missing values; ab245 missing values; ac28 
missing values; ad45 missing values; ae34 missing values; af524 missing values; ag223 missing values; ah223 missing values; ai245 missing values.
Table 2. (Continued)
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(p < 0.001)14 However, lung function was not 
assessed in either the COPD or the control group. 
To date, one population-based study by 
Andersson and colleagues has been published 
that included a large non-COPD control group 
(470 subjects with COPD and 659 without 
COPD, respectively).20 However, this study did 
not find a difference in fatigue level between 
patients with COPD and subjects without COPD. 
This might be attributed to the fact that the 
included patients with COPD had a lower disease 
severity compared with the patients in the current 
analysis (FEV1 86% versus 56% of predicted, 
33% versus 54% had a dyspnoea score ⩾2). 
Nevertheless, we also showed a significant, but 
poor, correlation between fatigue and airflow lim-
itation. Lastly, the current findings on the pro-
portion of patients with severe fatigue (49%) are 
in accordance with prevalence estimates of other 
airway diseases such as asthma (63%).38
Factors associated with fatigue in patients with 
COPD
There were no clear associations identified 
between fatigue and demographic characteris-
tics, clinical features and disease severity. In par-
ticular, a significant but poor correlation was 
found between fatigue and the degree of airflow 
limitation. This finding is in contrast with that of 
a previous study by Breslin and colleagues, who 
showed a significantly negative correlation 
between fatigue and FEV1 % predicted 
(r = −0.32; p < 0.05).24 The current findings 
are more in line with recent studies by Kapella 
and colleagues, Baghai-Ravary and colleagues, 
and Lewko and colleagues.9,18,19 Moreover, a 
longitudinal study on 77 patients with COPD 
showed that the lung function did not worsen 
during 4-year follow-up, while the proportion of 
patients with COPD with mild-to-severe fatigue 
doubled.16 These results strongly suggest that 
the degree of airflow limitation may not be the 
primary underlying cause of fatigue in patients 
with COPD.
The only moderate correlations found between 
demographic characteristics, clinical features, dis-
ease severity and fatigue concerned dyspnoea 
(rs = 0.35, p < 0.001) and the number of medica-
tions (rs = 0.35, p < 0.001). As expected, a signifi-
cant association was found between dyspnoea 
and fatigue, since these sensations are often 
reported to concur.9,15,47–49 Nevertheless, 
Reihstein and colleagues observed a correlation 
between fatigue and dyspnoea of a moderate 
magnitude (r = 0.43), similar to this study,47 
whereas studies by Gift and Shepard (r = 0.63), 
Woo and colleagues (r = 0.69), Kapella and col-
leagues (r = 0.74) and Kinsman and colleagues 
(r = 0.76) found a correlation of a large magnitude 
between fatigue and dyspnoea.9,15,48,49 The use of 
different measures to assess fatigue severity as 
well as dyspnoea severity might have influenced 
Figure 3. Scatterplot showing the poor association between fatigue and FEV1 (% predicted).
FEV1, forced expiratory volume over 1 s of predicted.
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these results. This is the first study to find a sig-
nificant positive correlation between the number 
of medications used and fatigue. The role of pul-
monary medication in the treatment of fatigue is 
probably limited since the degree of airflow limi-
tation is poorly associated with the fatigue. A 
causal relationship cannot be established based 
on the current cross-sectional data. Therefore, it 
remains unknown whether, and to what extent, 
this observation may be due to side effects of 
medication used, or may be caused by the condi-
tions for which the medications were prescribed. 
Future COPD drug trials may need to monitor 
fatigue as a possible adverse symptom.
Explained variance of fatigue in COPD
Although 30% of the variance in fatigue scores 
was explained by the demographic characteris-
tics, clinical features and disease severity, 70% of 
the variance remained unexplained in the present 
study. This indicates that fatigue is a complex 
symptom and the causes should be sought not 
only in conventional demographic characteristics, 
clinical features and disease characteristics only, 
but also rather in a combination of physical, psy-
chological, systemic and behavioural factors (pre-
cipitating and perpetuating factors).46
Strengths and limitations
Some limitations should be acknowledged. First, 
80% of the patients with COPD were classified 
as GOLD II and III, indicating that the current 
results cannot be generalized to patients with 
mild or very severe COPD. Second, the included 
patients with COPD were recruited from a sec-
ondary care setting. Therefore, results cannot be 
generalized to primary and tertiary care. Third, 
due to the retrospective nature of the analyses, it 
was not possible to retrieve information on the 
specific medication that was used by the partici-
pants, which could have given us insights into 
the relation between pulmonary medication and 
fatigue. Moreover, it should be noted that for 
some variables (e.g. pack years, use of long-term 
oxygen therapy, and the number of medica-
tions), not all data were available. For this rea-
son, the multiple regression model is based on 
data from 189 patients. Despite the smaller sam-
ple size, the results of the multiple regression 
indicate that the causes of fatigue cannot be 
explained only by demographics, clinical fea-
tures and disease severity. Factors such as 
depressive symptoms may potentially also con-
tribute to the explanation of fatigue in patients 
with COPD.12,13,18,50,51 Nevertheless, it may be 
difficult to distinguish if fatigue is a symptom of 
the depression itself, or emerges as an adverse 
effect of antidepressant drugs. Besides depres-
sive symptoms, patients with COPD also often 
report poor sleep quality.13 Moreover, patients 
with COPD and sleep apnoea (overlap syndrome 
patients) express significantly more fatigue than 
sleep apnoeic patients only.52 Therefore, unde-
tected sleep apnoea and poor sleep quality 
should be considered in future studies. In addi-
tion, factors such as physical inactivity and kine-
siophobia,20,53 but also other comorbidities like 
concomitant heart disease have been reported to 
be associated with fatigue in COPD and should 
be further explored.54 Low-grade systemic 
inflammation has also been observed in patients 
with clinically stable COPD.55 Nevertheless, to 
date, little research has been done to investigate 
which inflammatory markers are possibly related 
to fatigue in COPD.56,57 Fourth, because of the 
cross-sectional design, we were not able to exam-
ine whether the associations between fatigue and 
the conventional COPD characteristics were 
temporary or fluctuate over time. In light of this, 
the use of Ecological Momentary Assessment 
(EMA) would have provided us with more 
insight into the day-to-day variability of 
fatigue.46,58,59 Fifth, the direct impact of an exac-
erbation and, in particular, exacerbation-related 
hospitalization on fatigue could not be evalu-
ated. A longitudinal study design in which addi-
tional measurements are conducted during and 
after an exacerbation-related hospitalization 
Figure 4. Scatterplot showing the strong association 
between fatigue and the CAT.
CAT, COPD assessment test
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would provide us with more information on the 
impact of an exacerbation on fatigue.46 At last, 
information on the impact of fatigue on QoL 
and the relationship with commonly reported 
symptoms in COPD (such as cough and spu-
tum) should be described in future studies.46
Strengths of the current study are the large patient 
sample size as well as the inclusion of 199 non-
COPD control subjects with measured lung func-
tion. The differences in the cohorts increases the 
findings’ external validity and likelihood that the 
results are representative for the entire COPD 
population (Tables S3 and S5). The additional 
use of the validated CIS-Fatigue checklist enables 
the calculation of the prevalence of fatigue and 
the discrimination between normal, mild and 
severe fatigue.
Conclusion
This study corroborates earlier findings and dem-
onstrates that severe fatigue is highly prevalent 
and more common in patients with COPD com-
pared with non-COPD control subjects, and cor-
relates poorly with the degree of airflow limitation. 
These findings emphasize the clinical importance 
of assessing fatigue in patients with COPD. 
Moreover, the causes of fatigue in COPD should 
no longer be sought only in the demographic 
characteristics, clinical features, and disease 
severity. Future studies should focus on the influ-
ence of physical, psychological, behavioural, and 
systemic factors that could potentially precipitate 
or perpetuate fatigue in patients with COPD.
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